[go: up one dir, main page]

NO961900L - Metylenblått for behandling eller profylakse av encefalopati forårsaket av ifosfamid - Google Patents

Metylenblått for behandling eller profylakse av encefalopati forårsaket av ifosfamid

Info

Publication number
NO961900L
NO961900L NO961900A NO961900A NO961900L NO 961900 L NO961900 L NO 961900L NO 961900 A NO961900 A NO 961900A NO 961900 A NO961900 A NO 961900A NO 961900 L NO961900 L NO 961900L
Authority
NO
Norway
Prior art keywords
ifosfamide
methylene blue
prophylaxis
treatment
encephalopathy caused
Prior art date
Application number
NO961900A
Other languages
English (en)
Other versions
NO961900D0 (no
Inventor
Adrian Kuepfer
Thomas Cerny
Original Assignee
Univ Newcastle Ventures Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Newcastle Ventures Ltd filed Critical Univ Newcastle Ventures Ltd
Publication of NO961900L publication Critical patent/NO961900L/no
Publication of NO961900D0 publication Critical patent/NO961900D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Den encefalopati som forår- sakes av ifosfamid og lignende virkende forbindelser, kan forhindres eller be- handles ved administrering av metylen- blått eller en annen forbindelse som er i stand til å oksidere en redusert flavinrest. Pyritinol er i stand til å redusere andre aspekter av ifosfamid- toksisitet.
NO961900A 1993-11-12 1996-05-10 Metylenblått for behandling eller profylakse av encefalopati forårsaket av ifosfamid NO961900D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939323399A GB9323399D0 (en) 1993-11-12 1993-11-12 Pharmaceutical formulations
PCT/GB1994/002494 WO1995013079A1 (en) 1993-11-12 1994-11-14 Methylene blue for the treatment or prophylaxis of ancephalopathy caused by ifosfamide

Publications (2)

Publication Number Publication Date
NO961900L true NO961900L (no) 1996-05-10
NO961900D0 NO961900D0 (no) 1996-05-10

Family

ID=10745089

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961900A NO961900D0 (no) 1993-11-12 1996-05-10 Metylenblått for behandling eller profylakse av encefalopati forårsaket av ifosfamid

Country Status (9)

Country Link
US (1) US5854240A (no)
EP (1) EP0728005A1 (no)
JP (1) JPH09505042A (no)
CN (1) CN1134670A (no)
AU (1) AU8149594A (no)
CA (1) CA2176386A1 (no)
GB (1) GB9323399D0 (no)
NO (1) NO961900D0 (no)
WO (1) WO1995013079A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
US7176192B2 (en) * 2001-10-26 2007-02-13 Bionumerik Pharmaceuticals, Inc. Method for treating patients for radiation exposure
CA2379211A1 (fr) * 2002-03-28 2003-09-28 Institut De Cardiologie De Montreal Utilisation du bleu de methylene pour renverser la reaction hemodynamique exageree induite par la combinaison d'un derive nitre et du sildenafil ou d'une molecule de meme classe (inhibiteur de la phosphodiesterase)
US20060188866A1 (en) * 2005-02-18 2006-08-24 Children's Hospital Oakland Research Institute Diaminophenothiazine compositions and uses thereof
GR1006794B (el) * 2009-02-26 2010-06-04 Αλεξανδρος Βαμβακιδης Προσδετες των σιγμα υποδοχεων, αντι-αποπτωτικες και προ-αποπτωτικες ιδιοτητες επι των κυτταρικων μηχανισμων, και με πρωτοτυπη κυτταρο-προστατευτικη αλλα και αντικαρκινικη δραση
JP2010184936A (ja) * 2010-06-01 2010-08-26 Bionumerik Pharmaceuticals Inc 放射線被爆患者の処置方法
JPWO2021095696A1 (no) * 2019-11-11 2021-05-20

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1645921C3 (de) * 1966-07-11 1978-10-12 Asta-Werke Ag Chemische Fabrik, 4800 Bielefeld 2-Oxo-13,2-osazaphosphorinane, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
US4548927A (en) * 1983-05-25 1985-10-22 Eaton John W Method and agents for raising animal tolerance to oxidant stress-inducing antibiotics
EP0248803A4 (en) * 1985-02-12 1988-01-21 Commw Scient Ind Res Org VOLTAMETRIC CELL.

Also Published As

Publication number Publication date
US5854240A (en) 1998-12-29
CA2176386A1 (en) 1995-05-18
CN1134670A (zh) 1996-10-30
EP0728005A1 (en) 1996-08-28
GB9323399D0 (en) 1994-01-05
WO1995013079A1 (en) 1995-05-18
AU8149594A (en) 1995-05-29
JPH09505042A (ja) 1997-05-20
NO961900D0 (no) 1996-05-10

Similar Documents

Publication Publication Date Title
AU5669198A (en) Cyclosporin derivative, its preparation and pharmaceutical compositions containing same
AU9125191A (en) Retroviral protease inhibitors
NO20003233D0 (no) 4-hydrokykinolin-3-karboksamider og hydraziner som antivirale midler
MXPA04006553A (es) Compuesto de 4-oxoquinolina y uso del mismo como inhibidor de integrasa de vih.
UA42699C2 (uk) Бензоксазинонові сполуки, спосіб інгібування зворотної транскриптази, попередження або лікування, комбінації та фармацевтичні композиції
AU6949594A (en) Substituted oxazolyl compounds for the treatment of inflammation
NO940266L (no) Indre strålingsskade
NO953370D0 (no) Anvendelse av riluzol ved behandling av neuro-AIDS
RU94046070A (ru) Применение /(4-(1,4,5,6-тетрагидро-4-метил-6-оксо-3-пиридазинил)фенил)гидразоно/ пропандинитрила для лечения или профилактики ишемии миокарда, способ лечения ишемии миокарда
NO961900L (no) Metylenblått for behandling eller profylakse av encefalopati forårsaket av ifosfamid
DK0380331T3 (da) Anvendelse af di-tert.butylhydroxyphenylthioderivater til fremstilling af et lægemiddel til behandling eller forebyggelse af arteriosklerose eller atherosklerose
HU9601649D0 (en) Hiv protease inhibitors
GR3029370T3 (en) Compounds and methods for inhibition of hiv and related viruses
NO20040153L (no) Synergistisk farmasoytisk kombinasjon for profylakse eller behandling av diabetes
NO970340L (no) Organiske forbindelser
NO932431L (no) Fremgangsmaate og mellomprodukter for fremstilling av azabicyklo(2,2,2)oktan-3-iminer
AU3206297A (en) Composition and method for treating herpes simplex
AU4175893A (en) Treatment of inflammatory bowel disease
EA199800869A1 (ru) Лечение угрей
TW325997B (en) Pharmaceutical composition for preventing and treating retinal diseases
NO992008L (no) Nye (+)-enantiomerer av cis-3,4-kromanderivater som kan anvendes ved forhindring eller behandling av °strogenrelaterte sykdommer eller syndromer
NO992005L (no) Nye cis-3,4-kromanderivater som kan anvendes ved forhindring eller behandling av °strogenrelaterte sykdommer eller syndromer
DK0714393T3 (da) Thiazoler som antiviralt middel
AU5625194A (en) Rectal flunisolide compositions for treating inflammatory intestinal disorders
EP0774969B8 (en) Hiv protease inhibitor combination